



Ifw

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Confirmation No. 5303
	)	
Rainer K. BRACHMANN et al.	)	Group Art No. 1653
	)	
Serial No: 10/500,155	)	Examiner: TBA
	)	
Filed: October 29, 2004	)	Docket No. 004255.00027
	)	
For: Global Suppressors of p53 Mutations	)	

INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314


Dear Sir:

In accordance with 37 CFR §§1.97 and 1.98, enclosed is one (1) sheet of PTO Form 1449 listing documents for consideration by the Examiner during the prosecution of the subject application. Pursuant to the waiver by the U.S. Patent and Trademark Office of the requirement under 37 C.F.R. 1.98(a)(2)(i), a copy of the U.S. Patent reference is not submitted herewith.

Since this Information Disclosure Statement is being filed before issuance of a first Office Action on the merits under 37 C.F.R. 1.97(b), it is submitted that no fee or certification is required. However, if a fee is required, please charge our deposit account no. 19-0733.

Respectfully submitted,

Dated: June 12, 2006

By:   
Sarah A. Kagan  
Registration No. 32,141

Banner & Witcoff, Ltd.  
Customer No. 22907



Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number	10/500,155
Filing Date	October 29, 2004
First Named Inventor	Tian-Li Wang
Group Art Unit	1653
Examiner Name	TBA
Attorney Docket Number	004255.00027

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US 5, 840,579	11/24/1998	Boeke et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		TIMOTHY E. BARONI et al., "A Global Suppressor Motif for p53 Cancer Mutants," PNAS, April 6, 2004, pp. 4930-4935, Vol. 101, No. 14	
		RAINER K. BRACHMANN et al., "Genetic Selectin of Intragenic Suppressor Mutations that Reverse the Effect of Common p53 Cancer Mutations," The EMBO Journal, 1998, No. 7, pp1847-1859, Vol. 17	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231